About Us

Detroit R&D Inc. (DRD) is an NIH SBIR-sponsored company that specializes in the development and manufacture of ELISA, antibodies and assay kits for research, diagnosis and treatment of cardiovascular disease and cancer.

Detroit R&D was founded in 1997 by Dr. Hyesook Kim as a company dedicated to building a relationship of trust with the research community by providing the highest quality products through leading-edge technology. Detroit R&D has been steadily establishing itself as a worldwide source for novel diagnostic and drug-screening products. The Detroit R&D laboratories and offices are located in the heart of a new redevelopment district in the city of Detroit, Michigan.

Detroit R&D with an original project to develop easy and inexpensive hypertension kits for measuring novel fatty acid biomarkers in blood, urine and tissue has evolved to a company with leading-edge technologies in the fields of a) hypertension, stroke, cardiovascular diseases and diabetes (verified by >60 peer-reviewed publications by end-users), b) prostate, breast and lung cancer biomarkers, c) environmental estrogens such as BPA and BPS, d) COX-2 biomarker , e) cytochromes P450 (CYPs), f) oxidative stress, g) mitochondrial DNA damage and copy number, h) glycosylated c-myc, p53 and NF-kB, i) glycan microarrays, j) wound healing and k) label-free nanotechnology.

Detroit R&D has established a track record of success with a) sales of products to US and worldwide researchers by direct sales and via 24 distributors, b) 18 National Institutes of Health (NIH) SBIR Phases I and II (>10 million) awards to develop hypertension diagnostics, mitochondrial DNA damage assay, cancer microarrays, glycosylated biomarkers for prostate cancer, glycosylated proteins in breast cancer and circulating nucleic acid-based lung cancer biomarkers and c) 8 issued and 6 pending patents.

In summary, Detroit R&D has the talent, insight and drives to grow substantially. We welcome collaboration and/or licensing inquiries.

Mission

Mission of the Managing Personnel at Detroit R&D is to train and encourage employees to become "hong-ik-in-gahn" (men and women contributing to human wellbeing).

Detroit R&D's mission is to contribute to society by:

Developing leading-edge technologies

In-depth customer services

Being a partner in the improvement of Detroit

Contact Us

The Detroit R&D, Inc. laboratories are located at the Metropolitan Center for High Technology (MCHT), in downtown Detroit, Michigan.

Corporate Offices

Detroit R&D, Inc.
2727 Second Avenue, Suite 4113
Detroit, Michigan 48201, U.S.A.
Tel: (313) 961-1606
Fax: (313) 963-7130
info@DetroitRandD.com

Principal Investigators

Hyesook Kim, Ph.D.
Director of Research, President
hskim@DetroitRandD.com

Aby Joiakim, Ph.D.
Assistant Director of Research
abyj@DetroitRandD.com

Julia Santos, Ph.D.
Senior Scientist
jmsantos@detroitrandd.com

Patents

A. Human Hypertension Studies:

1. Detection of hypertension using glucuronidated metabolic products. US patent #7,695,927 (4/13/10)

2. Detection of hypertension using glucuronidated metabolic products: inhibitor (drug) screening tools. US patent #8,409,821 (4/2/13)

3. Detection of hypertension using immunoreactive metabolic products. US patent #6,440,682 and 6,534,282 (2 divisional patents issued on 8/27/02 & 3/18/2003, respectively).

B. Glycosylated transcriptional Factors, Glycosylated c-myc, p53, NF-kB

1. Glycosylated site-specific antibodies and anti-cancer compounds. US patent #10,317,409 (6/11/19)

C. TGF-beta subunit antibody production

1. Form-specific antibody production for cancer biomarkers, NAG-1, H6D and other TGF-beta subfamily. US patent #9,212,221 (12/15/15)

D. Microarray Technology

1. Chip production, hybridization, and data interpretation for antibody and protein microarrays. US patent #8,765,641 (7/1/14)

E. Other Patents

1. Assessment of oxidant stress in vitro and in vivo. US patent #6,812,212 (11/2/04).

2. Augmentation of wound healing by elF4E mRNA and EGF mRNA. US patent #7,202,226 (4/10/2007).

3. Bio-preservatives: A method for retarding bacterial growth in food by adding nitrate-rich plant extracts such as broccoli, Chinese cabbage and celery. USpatent #6,217,925 (4/17/2001).

Funding

NIH Funding (since 1998)

1. SBIR Phase I, “Immunoassays for metabolites of AA epoxygenases”, Completed.

2. SBIR Phase I, “Mutagenicity/genotoxicity assays with endogenous PGHS-2”, Completed.

3. NIH R15GM59595, Co-I."Role of cytochrome P450 in isoflavone metabolism", Completed.

4. SBIR Phase I, “Microarrays of X. laevis genes: a tool for Mol. Toxicology”, Completed.

5. SBIR Phase II, “Immunoassays for metabolites of AA epoxygenases”, Completed.

6. SBIR Phase II, “Mutagenicity/genotoxicity assays with endogenous PGHS-2”, Completed.

7. SBIR Phase II, “Targeted antibody microarrays: a tool for Toxicoproteomics”, Completed.

8. SBIR Phase II, “Microarrays of X. laevis genes: a tool for Mol. Toxicology”, Completed.

9. SBIR Phase I, “Fetal alcohol syndrome biomarkers by antibody microarray”, Completed.

10. SBIR Phase I, N43CN53306, “Antibody microarray for cancer detection” Completed.

11. STTR Phase I, R41CA105578, “A molecular signature of cell invasion in breast cancer”, Completed.

12. SBIR Phase II, “Targeted antibody microarrays: a tool for Toxicoproteomics”, Completed.

13. SBIR Phase I, “Diagnostic ELISA to measure prostate cancer biomarker in serum” Completed.

14. SBIR Phase II, “Diagnostic ELISA to measure prostate cancer biomarker in serum” Completed.

15. Supplementary fund for SBIR Phase II, Completed.

16. SBIR Phase I, “Novel HTS for gap junctional communication” Completed.

17. SBIR Phase I, "Site-specific antibodies for proteins in cancer" Completed.

18. SBIR Phase I, "Glycoproteins: Biomarkers for cancer and inflammatory diseases" Completed.

19. SBIR Phase II, "Site-specific antibodies for GlcNAcylated proteins in cancer" Active.

20. SBIR Phase I, "Circulating Nucleic Acid-Based Nano Technology in Cancer" Active.